

GenCore version 4.5							
Copyright (c) 1993 - 2000 Compugen Ltd.							
W Protein - protein search, using sw model							
run on:	August 29, 2001, 09:46:24	; search time 21.49 Seconds					
sequence:	1 LDLEDLYRPTWQLLGRAFVF.....DVALEHHHECDCYRGSTGG	136	(without alignments)				
scoring table:	BLOSUM62	383.660	Million cell updates/sec				
title:	US-09-457-066-2_COPY_210_345						
perfect score:	754						
sequence:	1 LDLEDLYRPTWQLLGRAFVF.....DVALEHHHECDCYRGSTGG	136					
searched:	412676 seqs, 60623988 residues						
total number of hits satisfying chosen parameters:	412676						
minimum DB seq length:	0						
maximum DB seq length:	20000000000						
post-processing:	Minimum Match 0%						
	Maximum Match 100%						
	Listing First 45 summaries						
database :							
A_Geneseq_0601:*							
1: /SIDS8/gcdata/geneseq/geneseqp/AA1980.DAT:*							
2: /SIDS8/gcdata/geneseq/geneseqp/AA1981.DAT:*							
3: /SIDS8/gcdata/geneseq/geneseqp/AA1982.DAT:*							
4: /SIDS8/gcdata/geneseq/geneseqp/AA1983.DAT:*							
5: /SIDS8/gcdata/geneseq/geneseqp/AA1984.DAT:*							
6: /SIDS8/gcdata/geneseq/geneseqp/AA1985.DAT:*							
7: /SIDS8/gcdata/geneseq/geneseqp/AA1986.DAT:*							
8: /SIDS8/gcdata/geneseq/geneseqp/AA1987.DAT:*							
9: /SIDS8/gcdata/geneseq/geneseqp/AA1988.DAT:*							
10: /SIDS8/gcdata/geneseq/geneseqp/AA1990.DAT:*							
11: /SIDS8/gcdata/geneseq/geneseqp/AA1991.DAT:*							
12: /SIDS8/gcdata/geneseq/geneseqp/AA1992.DAT:*							
13: /SIDS8/gcdata/geneseq/geneseqp/AA1993.DAT:*							
14: /SIDS8/gcdata/geneseq/geneseqp/AA1994.DAT:*							
15: /SIDS8/gcdata/geneseq/geneseqp/AA1995.DAT:*							
16: /SIDS8/gcdata/geneseq/geneseqp/AA1996.DAT:*							
17: /SIDS8/gcdata/geneseq/geneseqp/AA1997.DAT:*							
18: /SIDS8/gcdata/geneseq/geneseqp/AA1998.DAT:*							
19: /SIDS8/gcdata/geneseq/geneseqp/AA1999.DAT:*							
20: /SIDS8/gcdata/geneseq/geneseqp/AA2000.DAT:*							
21: /SIDS8/gcdata/geneseq/geneseqp/AA2001.DAT:*							
22: /SIDS8/gcdata/geneseq/geneseqp/AA2001.DAT:*							
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.							
SUMMARIES							
result No.	score	query	match length				
			DB ID				
1	754	100.0	318	21	AY84558		
2	754	100.0	339	21	AAB58438		
3	754	100.0	345	20	AY33679		
4	754	100.0	345	20	AY41766		
5	754	100.0	345	20	AY30023		
6	754	100.0	345	21	AAB48657		
7	754	100.0	345	21	AAB24250		
8	754	100.0	345	21	AAB44322		
9	754	100.0	345	21	AAB10633		
10	754	100.0	345	21	AAB10634		
11	754	100.0	345	21	AAB10635		
ALIGNMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
SUMMARIES							
result No.	score	query	match length				
			DB ID				
1	754	100.0	318	21	AY84558		
2	754	100.0	339	21	AAB58438		
3	754	100.0	345	20	AY33679		
4	754	100.0	345	20	AY41766		
5	754	100.0	345	20	AY30023		
6	754	100.0	345	21	AAB48657		
7	754	100.0	345	21	AAB24250		
8	754	100.0	345	21	AAB44322		
9	754	100.0	345	21	AAB10633		
10	754	100.0	345	21	AAB10634		
11	754	100.0	345	21	AAB10635		
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX							
KW	Platelet-derived growth factor C; PDGF-C; cell proliferation; connective tissue; growth factor; heparin; platelet; wound healing; VEGF-F;						
KW							
KW	fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;						
KW							
KW	lung carcinoma; erythroleukemia; tissue remodelling.						
OS	Homo sapiens.						
XX							
Key	FH	Location/Qualifiers					
FT	FT	note= "encoded by AAS"					
XX							
ALIGMENTS							
RESULT	1						
ID	AY84558	standard; Protein;	318 AA.				
XX							
AY84558;							
AC							
XX							
DT	25-JUL-2000	(first entry)					
XX							
DE	A fragment of platelet-derived growth factor C (PDGF-C).						
XX</td							

XX (LUDWIG INST CANCER RES.
PA (UYHE-) UNIV HELSINKI LICENSING LTD.
XX

PI Eriksson U, Aase K, Lee X, Ponten A, Utela M, Alitalo K;
PI Oestman A, Heldin C, Betsholtz C;
XX

DR WPI: 2000-292954/25.
DR -N-PSDB; AAK12524.

XX Novel DNA encoding PDGF-C useful to stimulate or enhance proliferation,
PT differentiation, growth and motility of cells expressing the PDGF-C
receptor -
XX

PS Disclosure; Fig 4; 135pp; English.

XX The present sequence represents a human platelet-derived growth factor C
CC (PDGF-C) (formally designated VEGF- β) fragment. PDGF-C polypeptides have
CC the ability to stimulate and enhance proliferation or differentiation,
CC and/or growth or motility of cells expressing PDGF-C receptor.
CC PDGF-C polypeptides can be used in pharmaceuticals for promoting cell
CC proliferation, preferably in combination with one other growth factor
CC and heparin. Pharmaceuticals comprising PDGF-C polypeptides can also
CC be used for stimulating connective tissue or wound healing. The
CC truncated form of PDGF-C and used to regulate the receptor-binding
CC specificity of PDGF-C. PDGF-C can also be used to promote fibroblast
CC mitogenesis in a mammal and to induce PDGF alpha receptor activation.
CC PDGF-C antagonists can be used to inhibit tumour growth of a tumour
CC expressing PDGF-C in a mammal. Specific types of human tumours, e.g.
CC choriocarcinoma, Wilms tumour, megakaryoblastic leukaemia, lung carcinoma
CC and erythroleukemia, can be identified by testing for expression of
CC PDGF-C. PDGF-C antagonists can also be used to inhibit tissue
CC remodelling during invasion of tumour cells into a normal population of
CC cells. Antagonists can also be used to treat fibrotic conditions,
CC especially found in the lung, kidney or liver.
XX

Sequence 318 AA;

Query Match 100.0%; Score 754; DB 21; Length 318;
Best Local Similarity 100.0%; Pred. No. 4.3e-71;
Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LDLEDLYRPTWQLQKAFVGRKSRVVDNLTEEVRLYSCTPRNFSVSTREELKRTDTI 60
Db 183 1dledlyrptwqlqkafvgrksrvvdnlteevrlsctprnfsvstrelkrtdti 242
Qy 61 FWPGCLLVRKGIGNCACCLHNCQCVPSKVTKKYHEVQLRPTGVRLKHSITDVAL 120
Db 243 fwpgcllvrkgicacclhncqcvpskvtkkyhevqlrptgvrlkhsitdval 302
Qy 121 EHHEECDCVCRGSGTG 136
Db 303 ehheecdcvcrgsgtg 318

RESULT 2
AA58438
ID AAB58438 standard; Protein: 339 AA.
XX
AC AAB58438;

XX DT 14-MAR-2001 (first entry)
XX DE Lung cancer associated polypeptide sequence SEQ ID 776.
DE
XX KW Human; lung cancer associated protein; neuroprotective; cytostatic;
KW cardioactive; immunomodulatory; muscular active; pulmonary;
KW gastrointestinal; nephrotropic; antiinfective; gynecological;
KW antibacterial; diagnosis; neural disorder; immune disorder; reproductive;
KW proliferative disorder; wound healing; infectious disease.
XX

OS Homo sapiens.
XX WO00055180-22.
PN XX
XX 21-SEP-2000.
XX 08-MAR-2000; 2000WO-US5918.
XX 12-MAR-1999;
PR 99US-0124270.
XX (HUMA-) HUMAN GENOME SCI INC.
PA (ROSE-) ROSEN C A.
XX
PI Ruben SM;
XX
DR WPI; 2000-587514/55.
DR N-PSDB; AAF1314.

XX Lung cancer associated gene sequences, referred to as lung cancer
PT antigens, useful for treatment, prevention, and diagnosis of disorders
PT such as lung cancer -
XX
PS Claim 11; Page 1305-1306; 1425pp; English.
XX Polynucleotide sequences AAF17982 - AAF18424 encode human lung cancer
CC associated proteins represented in AAB58106 - AAB58548. Lung cancer
CC associated proteins and polynucleotide sequences, their agonists, and
CC antagonists may have neuroprotective; cytostatic; cardioactive;
CC immunomodulatory; muscular active general; pulmonary; gastrointestinal
CC general; nephrotropic; antiinfective; gynecological; or antibacterial
CC activity. The invention also includes antibodies specific for the
CC protein or polynucleotide sequences. The lung cancer associated
CC polynucleotide sequences may be used for detection of lung cancer,
CC chromosome identification, as chromosome markers, and for numerous other
CC disorders such as neural, immune, muscular, reproductive,
CC gastrointestinal, pulmonary, cardiovascular, renal, and proliferative
CC disorders. The proteins may also be used in the treatment of wounds and
CC infectious diseases. Polynucleotide sequences AAF18425 - AAF18433 and
CC peptide AAB58549 are used in the course of the invention for the
CC identification and characterisation of the polynucleotide and protein
CC sequences.
XX
SQ Sequence 339 AA;

Query Match 100.0%; Score 754; DB 21; Length 339;
Best Local Similarity 100.0%; Pred. No. 4.6e-71;
Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LDLEDLYRPTWQLQKAFVGRKSRVVDNLTEEVRLYSCTPRNFSVSTREELKRTDTI 60
Db 204 1dledlyrptwqlqkafvgrksrvdnlteevrlsctprnfsvstrelkrtdti 263
Qy 61 FWPGCLLVRKGIGNCACCLHNCQCVPSKVTKKYHEVQLRPTGVRLKHSITDVAL 120
Db 264 fwpgcllvrkgicacclhncqcvpskvtkkyhevqlrptgvrlkhsitdval 323
Qy 121 EHHEECDCVCRGSGTG 136
Db 324 ehheecdcvcrgsgtg 339

RESULT 3
AY33679
ID AAY33679 standard; Protein: 345 AA.
XX
AC AAY33679;
XX DT 11-JAN-2000 (first entry)
XX DE Human VEGF-E protein.
XX

KW VEGF-E; human; vascular endothelial cell growth factor; wound repair; treatment; cardiovascular disorder; endothelial disorder; therapy; tissue generation; regeneration; cardiac hypertrophy; cancer; detection; angiogenic disorder; age-related macular degeneration; vascular disease; neovascularization; tumor; gene mapping.

XX OS Homo sapiens.

XX PN WO9947677-A2.

XX PD 23-SEP-1999.

XX PF 10-MAR-1999; 99WO-US05190.

XX PR 17-MAR-1998; 98US-0040220.

XX PR 02-NOV-1998; 98US-0184216.

PA (GETH) GENENTECH INC.

XX PI Ferrara N, Kuo SS;

XX WPI; 1999-580306/49.

DR N-PSDB; AAZ23391.

XX New growth factor polypeptide useful for treating cardiovascular or endothelial disorders, e.g. cardiac hypertrophy

XX PS Claim 1; Fig 2; 12pp; English.

XX This invention describes the isolation of a novel human vascular endothelial cell growth factor-E (VEGF-E) polypeptide which has therapeutic, vasoactive and cardiotonic activity. VEGF-E can be administered therapeutically, especially by expressing encoding polynucleotides, to treat cardiovascular or endothelial disorders in mammals, especially humans. It is useful in wound repair and tissue regeneration and regeneration, and may especially be used to treat cardiac hypertrophy. It can be combined with a carrier in pharmaceutical compositions, which can be administered to treat disorders as above. VEGF-E can be used to screen for antagonists and agonists, and the antagonists administered to treat angiogenic disorders in mammals (especially humans) e.g. cancer or age-related macular degeneration. It can be used to generate antibodies, useful therapeutically as antagonists, as above. The antibodies are also useful to detect VEGF-E polypeptide, especially to diagnose cardiovascular, endothelial or angiogenic disorders in mammals (e.g. vascular disease, or neovascularization associated with tumor formation), by contacting the antibody with a tissue sample and detecting formation of an antibody-VEGF-E polypeptide complex. Polynucleotides encoding VEGF-E can be used to diagnose cardiovascular and endothelial disorders in mammals, by detecting abnormally high or low VEGF-E gene expression in tissue samples. They can also be used to diagnose a disease or susceptibility to a disease related to a mutated form of VEGF-E (e.g. a cardiovascular, endothelial or angiogenic disorder such as a tumor), by detecting a mutation in the VEGF-E encoding sequence isolated from a sample. They may also be used to produce probes useful to detect related sequences or for gene mapping. This sequence represents the human VEGF-E protein described in the method of the invention.

XX Sequence 345 AA;

Db 330 ||||||| standard; Protein; 345 AA.

RESULT 4

AAV41766
ID AAV41766 standard; Protein; 345 AA.
XX AAV41766;
AC AAV41766;
XX DT 07-DEC-1999 (first entry)
XX DE Human PRO200 protein sequence.
XX Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation; probe; blood coagulation disorder; cancer; cellular adhesion disorder; secreted protein; transmembrane protein.
XX OS Homo sapiens.
PN WO946281-A2.
XX PR 16-SEP-1999.
XX PF 08-MAR-1999; 99WO-US05028.
XX PR 10-MAR-1998; 98US-0077450.
PR 11-MAR-1998; 98US-0077632.
PR 11-MAR-1998; 98US-0077641.
PR 11-MAR-1998; 98US-0077649.
PR 12-MAR-1998; 98US-0077791.
PR 12-MAR-1998; 98US-0077792.
PR 13-MAR-1998; 98US-0078004.
PR 13-MAR-1998; 98US-0078020.
PR 17-MAR-1998; 98US-0078886.
PR 20-MAR-1998; 98US-0078910.
PR 20-MAR-1998; 98US-0078936.
PR 20-MAR-1998; 98US-0078939.
PR 25-MAR-1998; 98US-0079294.
PR 26-MAR-1998; 98US-0079656.
PR 27-MAR-1998; 98US-0079663.
PR 27-MAR-1998; 98US-0079664.
PR 27-MAR-1998; 98US-0079689.
PR 27-MAR-1998; 98US-0079728.
PR 27-MAR-1998; 98US-0079786.
PR 30-MAR-1998; 98US-0079920.
PR 30-MAR-1998; 98US-0079923.
PR 31-MAR-1998; 98US-0080105.
PR 31-MAR-1998; 98US-0080107.
PR 31-MAR-1998; 98US-0080165.
PR 31-MAR-1998; 98US-0080194.
PR 01-APR-1998; 98US-0080327.
PR 01-APR-1998; 98US-0080328.
PR 01-APR-1998; 98US-0080333.
PR 01-APR-1998; 98US-0080334.
PR 08-APR-1998; 98US-0081049.
PR 08-APR-1998; 98US-0081070.
PR 08-APR-1998; 98US-0081071.
PR 09-APR-1998; 98US-0081195.
PR 09-APR-1998; 98US-0081203.
PR 09-APR-1998; 98US-0081229.
PR 15-APR-1998; 98US-0081817.
PR 15-APR-1998; 98US-0081838.
PR 15-APR-1998; 98US-0081952.
PR 15-APR-1998; 98US-0081955.
PR 21-APR-1998; 98US-0082568.
PR 21-APR-1998; 98US-0082569.
PR 22-APR-1998; 98US-0082700.
PR 22-APR-1998; 98US-0082704.
PR 22-APR-1998; 98US-0082804.
PR 23-APR-1998; 98US-0082767.
PR 23-APR-1998; 98US-0082796.
PR 27-APR-1998; 98US-0083336.
PR 28-APR-1998; 98US-0083322.

Query Match 100.0%; Score 754; DB 20; Length 345;
Best Local Similarity 100.0%; Pred. No. 4.7e-71;
Matches 116; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 LDLEDLYRPTWOLIGKAVFGRSRVDFNLNLTEEVRLYSPCTPNEVSYTRTEELKRTDTI 60
Db 210 1dledlyRptwoligkavfgrsrvdfnlnlteevrllyspctpnevsytreelkrtdti 269

Qy 61 FWPCLLYKRCGGNCACCLNCACOYPSKTVTKYHEVYLQLRPTGYRGLHKSLLTDVAL 120
Db 270 fwpgcllykrcggncaccjhnncacqcvpskvtkkyhevylqrlptgyrlhkslltdval 329

Qy 121 EHHECDCYCRGSTGG 136

PR 29-APR-1998; 98US-0083392. Qy 1 LDLEDLYRPTWQLLGKAFVGRKSRVVDLNLLTEEVRLYSTPRNFSVSRBELKRTDTI 60
 PR 29-APR-1998; 98US-0083495. Db 210 ldledlyrptwqllgkafvgrksrvvdlnllteevrlystprnfsvireelkrtti 269
 PR 29-APR-1998; 98US-0083496. PR 29-APR-1998; 98US-0083499. Qy 61 FWPGCLIVKRCGGNCACCLHNCNECQCVPSKVKYHEVLQLRPKTGVLHKSLTDVAL 120
 PR 29-APR-1998; 98US-0083500. PR 29-APR-1998; 98US-0083515. Db 270 fwpgclivkrcggncacclhncneccvpskvtkkyhevlgirpkctvrglnksldval 329
 PR 29-APR-1998; 98US-0083524. PR 29-APR-1998; 98US-0083558. PR 29-APR-1998; 98US-0083559. PR 30-APR-1998; 98US-0083742. PR 05-MAY-1998; 98US-0084166. PR 06-MAY-1998; 98US-0084414. PR 06-MAY-1998; 98US-0084441. PR 07-MAY-1998; 98US-0084498. PR 07-MAY-1998; 98US-0084598. PR 07-MAY-1998; 98US-0084600. PR 07-MAY-1998; 98US-0084627. PR 07-MAY-1998; 98US-0084637. PR 07-MAY-1998; 98US-0084639. PR 07-MAY-1998; 98US-0084640. PR 07-MAY-1998; 98US-0084643. PR 13-MAY-1998; 98US-008523. PR 13-MAY-1998; 98US-0085338. PR 13-MAY-1998; 98US-0085339. PR 15-MAY-1998; 98US-0085573. PR 15-MAY-1998; 98US-0085579. PR 15-MAY-1998; 98US-0085580. PR 15-MAY-1998; 98US-0085582. PR 15-MAY-1998; 98US-0085689. PR 15-MAY-1998; 98US-0085697. PR 15-MAY-1998; 98US-0085700. PR 18-MAY-1998; 98US-0085704. PR 22-MAY-1998; 98US-0085623. PR 22-MAY-1998; 98US-0086392. PR 22-MAY-1998; 98US-0086414. PR 22-MAY-1998; 98US-0086430. PR 22-MAY-1998; 98US-0086486. PR 28-MAY-1998; 98US-0087098. PR 28-MAY-1998; 98US-0087106. PR 28-MAY-1998; 98US-0087208. PR 30-JUL-1998; 98US-0094651. PR 11-SEP-1998; 98US-0100038. XX (GETH) GENENTECH INC.
 XX Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J; PI
 XX WPI: 1999-551358/46. DR
 XX N-PSDB; AAX23496. DR
 XX New secreted and transmembrane polypeptides and their polynucleotides, cancers and cellular adhesion disorders - PT
 PT useful for treating blood coagulation disorders, cancers and cellular adhesion disorders - PT
 XX Claim 12; Fig 207; 530pp; English.
 XX The present invention describes secreted and transmembrane polypeptides and their polynucleotides. The nucleotide sequences are useful as sources of probes, primers, for chromosome mapping, and for generation of antisense sequences. They can also be used to create transgenic animals. The proteins can be used to treat a variety of diseases and disorders, depending on their function. Diseases that may be treated include blood coagulation disorders, cancers and cellular adhesion disorders. They may also be used to raise antibodies. AAZ33891 to CC polypeptide sequence given in the exemplification of the present invention.
 XX Sequence 345 AA:
 PR 1 LDLEDLYRPTWQLLGKAFVGRKSRVVDLNLLTEEVRLYSTPRNFSVSRBELKRTDTI 60
 PR 210 ldledlyrptwqllgkafvgrksrvvdlnllteevrlystprnfsvireelkrtti 269
 PR 61 FWPGCLIVKRCGGNCACCLHNCNECQCVPSKVKYHEVLQLRPKTGVLHKSLTDVAL 120
 PR 270 fwpgclivkrcggncacclhncneccvpskvtkkyhevlgirpkctvrglnksldval 329
 PR 121 EHHEECDOVCRSTGG 136
 PR 330 ehheecdccvcrstgg 345
 RESULT 5
 AAY30023 standard; Protein; 345 AA.
 XX
 XX AAY30023;
 XX DT 11-OCT-1999 (first entry)
 XX DE Human vascular endothelial growth factor related protein.
 XX KW Vascular endothelial growth factor related protein; VEGF-R protein; tissue growth inhibition; tumour growth; cancer; tissue growth; angiogenesis; coronary artery blockage.
 XX OS Homo sapiens.
 XX PN WO937671-A1.
 XX PD 29-JUL-1999.
 XX PF 26-JAN-1999; 99WO-US01574.
 XX PR 31-AUG-1998; 98US-0098548.
 XX PR 27-JAN-1998; 98US-0072635.
 XX PR 05-JUN-1998; 98US-008089.
 XX PR 24-JUN-1998; 98US-0090544.
 XX PA (ELIL) LILLY & CO ELI.
 XX Dou S, Na S, Song HY;
 XX PI Page 56-58; 62pp; English.
 XX DR WPI: 1999-458680/38.
 XX DR N-PSDB; AAX88352.
 XX A vascular endothelial growth factor related protein and related compounds
 PT polynucleotide, useful for identifying antagonists and binding PT compounds
 PT
 XX Claim 1; Page 56-58; 62pp. English.
 XX The present sequence represents a vascular endothelial growth factor CC related (VEGF-R) protein. VEGF-R can be used in assays to identify CC compounds that bind to it or that antagonize its activity. VEGF-R CC antagonists (e.g. anti-VEGF-R antibodies) are useful for inhibiting CC tissue growth. This is useful for inhibiting tumour growth and for CC treating cancer. VEGF-R itself can be used to stimulate tissue CC growth, angiogenesis and to treat coronary artery blockage. The CC VEGF-R coding sequence can be used for the recombinant production of CC the VEGF-R protein.
 XX Sequence 345 AA:
 Query Match 100.0%; Score 754; DB 20; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71; Mismatches 0; Indels 0; Gaps 0;
 Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 PR 1 LDLEDLYRPTWQLLGKAFVGRKSRVVDLNLLTEEVRLYSTPRNFSVSRBELKRTDTI 60
 PR 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 210 1dledlyrptwqlqkafvfgrksrvvdnliteevrlyscsprnfsireelkrtdti 269
 QY 61 FWPCCLLYKRCGGNCACCLHNCNEQCPSKVTKXHEVILQLRPTGVRLHKSLTDVAL 120
 Db 270 fwpccllvkrccgacclhncneqcqcvpskvtkxhevilqrlpktrgvlhksltval 329
 QY 121 EHHEECDCYCRGSSTGG 136
 Db 330 ehheecdvcvrgs99 345

RESULT 6

AAB48657 standard; Protein; 345 AA.
 XX

AAB48657;
 XX

DT 09-MAR-2001 (first entry)

DE Human zvegf3, SEQ ID NO:33.

Human; zvegf3; zvegf4 fusion; growth factor homologue; VEGF/PDGF family;
 CUB domain; PDGF-like activity; mitogenic; osteogenic;
 neovascularisation; tissue repair; proliferation; differentiation;
 liver damage; neuroregeneration; Alzheimer's disease; multiple sclerosis;
 periodontal disease; bone fracture; wound healing; vulnerability; ischaemia;
 immunomodulation; hepatic.

XX Homo sapiens.

XX WO200066736-A1.

XX PD 09-NOV-2000.

XX PF 03-MAY-2000; 2000WO-US40047.

XX PR 03-MAY-1999; 99US-0304216.

PR 10-NOV-1999; 99US-0164463.

PR 04-FEB-2000; 2000US-0180169.

XX PA (ZYMO) ZYMOGENETICS INC.

PI Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;

XX OS Homo sapiens

DR WPI; 2000-687541/67.

DR N-PSDB; AAC81582.

XX Growth factor homologs and the nucleic acids that encode them, useful
 PT e.g. for treating liver damage, ischemia, multiple sclerosis and
 PT Alzheimer's disease -
 XX PS Claim 48; Page 125-126; 143pp; English.

XX The invention relates to the human growth factor homologue zvegf4
 CC (AAB48655), and nucleic acids encoding it (AAC81555). Zvegf4 is a member
 CC of the PDGF (platelet-derived growth factor)/VEGF (vascular endothelial
 CC growth factor) family. Zvegf4 has a growth factor domain (AAB48654)
 CC characterised by a PDGF cystine knot structure, and a CUB domain
 CC (AAB48655) which has a beta barrel structure. Zvegf4 has PDGF-like
 CC activity, having mitogenic activity on fibroblasts, vascular smooth
 CC muscle cells and pericytes, and has also been shown to stimulate bone
 CC growth. The invention also relates to fusion proteins comprising human
 CC zvegf4 or fragments thereof, particularly human zvegf4/human zvegf3
 CC fusions, expression constructs and host cells comprising human zvegf4
 CC nucleic acids; the recombinant expression of human zvegf4; an antibody
 CC which binds to human zvegf4 or a fragment thereof; a method of activating
 CC a cell-surface PDGF receptor using a zvegf4-derived polypeptide; a
 CC method of modulating the proliferation, differentiation, migration or
 CC metabolism of bone cells, comprising exposing bone cells to
 CC zvegf4-derived polypeptides; and a method of detecting a genetic
 CC abnormality in the zvegf4 gene of a patient. Zvegf4 proteins and derived
 CC fragments may be used to stimulate tissue development or repair, or
 CC cellular differentiation or proliferation. They are particularly used for

CC the treatment or repair of liver damage, and may also be used to
 CC modulate neutite growth (e.g., in the treatment of Alzheimer's disease or
 CC multiple sclerosis). Due to their osteogenic activity, they may be used
 CC in the treatment of periodontal disease and fractures. They may also be
 CC used to enhance expansion of haemopoietic stem cells
 CC and endothelial precursor stem cells, which may be useful in the
 CC treatment of ischaemia, in wound healing, and in the modulation of the
 CC immune system. The present sequence represents human zvegf3.

XX Sequence 345 AA;
 SQ

RESULT 6
 AAB48657 standard; Protein; 345 AA.

XX ID AAB24250 standard; Protein; 345 AA.
 XX ID AAB24250

AC AAB24250;
 XX

DT 08-FEB-2001 (first entry)

DE Human platelet-derived growth factor related protein LP8.

XX Human; platelet derived growth factor related protein; LP8; VPGFh;

XX KW vascular endothelial growth factor h; tissue regenerator; pulmonary;

KW atherosclerosis; PDGF-related protein; antiarteriosclerotic.

DB 330 ehheecdvcvrgs99 345

RESULT 7
 AAB24250

XX ID AAB24250 standard; Protein; 345 AA.

XX AC AAB24250;

XX DT 08-FEB-2001 (first entry)

DE Human platelet-derived growth factor related protein LP8.

XX Human; platelet derived growth factor related protein; LP8; VPGFh;

KW vascular endothelial growth factor h; tissue regenerator; pulmonary;

KW atherosclerosis; PDGF-related protein; antiarteriosclerotic.

DB 330 Homo sapiens

XX OS Homo sapiens

PN WO200053940-A2.

XX PR 06-APR-1999; 99US-0127913.

XX PA (ELI LILLY & CO ELI.

XX PT 12-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US06427.

XX PR 06-APR-1999; 99US-0127913.

XX PA (ELI LILLY & CO ELI.

XX PT 12-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US06427.

XX PR 06-APR-1999; 99US-0127913.

XX PA (ELI LILLY & CO ELI.

XX PT 12-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US06427.

XX PR 06-APR-1999; 99US-0127913.

XX PA (ELI LILLY & CO ELI.

XX PT 12-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US06427.

XX PR 06-APR-1999; 99US-0127913.

XX PA (ELI LILLY & CO ELI.

XX PT 12-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US06427.

XX PR 06-APR-1999; 99US-0127913.

XX PA (ELI LILLY & CO ELI.

XX PT 12-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US06427.

XX PR 06-APR-1999; 99US-0127913.

XX PA (ELI LILLY & CO ELI.

XX PT 12-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US06427.

muscle growth. Antagonists of LP8 are useful for treating atherosclerosis. The present sequence represents human LP8, which is also called VEGF₈.

Sequence 345 AA;
 Query Match 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC 1 LDLEDLYRPTWQLGKAFYGRKSRVWDNLITEEVRILYSCTPRNFSVSTREBLKRTDTI 60
 CC 210 1dledlyrptwqlgkafygrksrvwdnliteevrilysctprnfsvstrelkrtdi 269
 CC 61 FWPGCLLWKRGGNCACCLHNCACQCVPSKVTKRYHEVQLRPTGVRGHLKSLTDVAL 120
 CC 270 fwpgcllwkrgncacclhncacqcvpskvtkryhevqlrptgvrghlsldval 329
 CC 121 EHHEECDYCGRGSGG 136
 CC 330 ehheecdycvrgstgg 345

RESULT 8
 AAB44322 standard; Protein: 345 AA.
 XX AAB44322;
 XX 08-FEB-2001 (first entry)
 DE Human PRO200 (UNQ174) protein sequence SEQ ID NO:488.
 KW Human; secreted protein; transmembrane protein; PRO; EST; cytosatic; expressed sequence tag; detection; cancer.
 XX Homo sapiens.
 XX WO200053756-A2.
 PD 14-SEP-2000.
 XX 18-FEB-2000; 2000WO-US04341.
 XX 08-MAR-1999; 99WO-US05028.
 PR 12-MAR-1999; 99US-0123957.
 PR 29-MAR-1999; 99US-0126773.
 PR 28-APR-1999; 99US-0130232.
 PR 14-MAY-1999; 99US-0131445.
 PR 23-JUN-1999; 99US-0141037.
 PR 26-JUL-1999; 99US-0145698.
 PR 29-OCT-1999; 99US-0162506.
 PR 30-NOV-1999; 99US-028313.
 PR 02-DEC-1999; 99WO-US28551.
 PR 02-DEC-1999; 99WO-US28555.
 PR 16-DEC-1999; 99WO-US30095.
 PR 30-DEC-1999; 99WO-US31243.
 PR 30-DEC-1999; 99WO-US31274.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00277.
 PR 06-JAN-2000; 2000WO-US00376.

XX (GETH) GENENTECH INC.
 XX Ashkenazi AJ, Baker KB, Botstein D, Desnoyers L, Eaton DL;
 PR Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PR Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillian KJ;
 PR Kijavim IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA;
 PR Shelton DL, Stewart TA, Tumas D, Williams PM, Wood WI;
 XX XX (JANCS) JANSSEN PHARM NV.
 PI Gordon RD, Sprengel JJ, Yon JR, Dijkmans JJJH, Gossiewska A;
 PI Dhanaraj SN, Xu J;

DR N-PSDB; AAC78582.
 XX Novel PRO polypeptides and polynucleotides used in detection methods,
 PT to target bioactive molecules to specific cells, and to modulate
 PT cellular activities -
 XX
 PS Claim 12; Fig 207; 636pp; English.
 XX AAC78458 to AAC78599 represent polynucleotide and EST (expressed sequence tag) sequences which encode secreted or transmembrane PRO polypeptides. The PRO polynucleotides and polypeptides have cytostatic activity. The polynucleotides and polypeptides can be used for detecting the presence of PRO polypeptides in samples, for linking bioactive molecules to cells and for modulating biological activities of cells, using the polypeptides for specific targeting. The polypeptide targeting can be used to kill the target cells, e.g. for the treatment of cancers. The polypeptide pairs provide specific targeting of bioactive molecules to cells. AAC78600 to AAC78887 represent PCR primers and probes used in the isolation of the PRO polynucleotide sequences.
 XX Sequence 345 AA;
 XX
 Query Match 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC 1 LDLEDLYRPTWQLGKAFYGRKSRVWDNLITEEVRILYSCTPRNFSVSTREBLKRTDTI 60
 CC 210 1dledlyrptwqlgkafygrksrvwdnliteevrilysctprnfsvstrelkrtdi 269
 CC 61 FWPGCLLWKRGGNCACCLHNCACQCVPSKVTKRYHEVQLRPTGVRGHLKSLTDVAL 120
 CC 270 fwpgcllwkrgncacclhncacqcvpskvtkryhevqlrptgvrghlsldval 329
 CC 121 EHHEECDYCGRGSGG 136
 CC 330 ehheecdycvrgstgg 345
 XX
 Query Match 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC 1 LDLEDLYRPTWQLGKAFYGRKSRVWDNLITEEVRILYSCTPRNFSVSTREBLKRTDTI 60
 CC 210 1dledlyrptwqlgkafygrksrvwdnliteevrilysctprnfsvstrelkrtdi 269
 CC 61 FWPGCLLWKRGGNCACCLHNCACQCVPSKVTKRYHEVQLRPTGVRGHLKSLTDVAL 120
 CC 270 fwpgcllwkrgncacclhncacqcvpskvtkryhevqlrptgvrghlsldval 329
 CC 121 EHHEECDYCGRGSGG 136
 CC 330 ehheecdycvrgstgg 345
 XX
 RESULT 9
 AAB10633 standard; Protein: 345 AA.
 ID AAB10633
 XX AAB10633;
 AC AAB10633;
 XX 19-JAN-2001 (first entry)
 DE Human RACE generated VEGF-X protein.
 XX VEGF-X; vascular endothelial growth factor; human; pulmonary; cytostatic;
 KW antirheumatic; antiarthritic; antipsoriatic; antidiabetic; treatment;
 KW angiogenesis regulator; vascular regulator; cancer; psoriasis;
 KW rheumatoid arthritis; diabetic retinopathy; blood vessel; organ repair;
 KW tissue regeneration; tissue repair; wound; dermal ulcer; pressure sore;
 KW venous sore; diabetic ulcer; burns; skin graft growth.
 XX Homo sapiens.
 OS WO200037641-A2.
 XX 29-JUN-2000.
 XX 21-DEC-1999; 99WO-US30503.
 XX
 PN WO200037641-A2.
 XX 29-JUN-2000.
 XX 21-DEC-1999; 99WO-US30503.
 XX
 PR 22-DEC-1998; 98GB-0028377.
 PR 18-MAR-1999; 99US-0124967.
 PR 08-NOV-1999; 99US-01164131.
 PR (JANCS) JANSSEN PHARM NV.
 XX
 PI Gordon RD, Sprengel JJ, Yon JR, Dijkmans JJJH, Gossiewska A;
 PI Dhanaraj SN, Xu J;

PN WO200037641-A2.
 XX KW angiogenesis regulator; vascularization regulator; cancer; psoriasis;
 PD KW rheumatoid arthritis; diabetic retinopathy; blood vessel; organ repair;
 XX KW tissue regeneration; tissue repair; wound; dermal ulcer; pressure sore;
 PF KW venous sore; diabetic ulcer; burns; skin graft growth.
 XX OS Homo sapiens.
 XX PN WO200037641-A2.
 XX PD 29-JUN-2000.
 XX XX 29-JUN-2000.
 XX XX 99WO-US30503.
 PR 22-DEC-1998; 98GB-0028377.
 PR 18-MAR-1999; 99US-0124567.
 PR 08-NOV-1999; 99US-0164131.
 XX XX (JAN) JANSSEN PHARM NV.
 PA Gordon RD, Sprengel JJ, Yon JR, Dijkmans JH, Gosiewska A;
 PT Dhanaraj SN, Xu J.;
 PI XX DR 2000-442669/38.
 DR N-PSDB; AAA71955.
 XX PS (JAN) JANSSEN PHARM NV.
 PT New vascular endothelial growth factor protein, useful for treating or
 PT preventing diseases associated with inappropriate angiogenesis activity
 PT such as cancer, rheumatoid arthritis, psoriasis and wounds -
 PT XX Disclosure; Fig 9; 127pp; English.
 XX This invention describes a novel vascular endothelial growth factor-X
 CC (VEGF-X) protein (ta) and its encoding polynucleotide (ta) which has
 CC vulnerability, cytostatic, antirheumatic, antiarthritic, antipsoriatic and
 CC antidiabetic activity and acts as an angiogenesis and vascularization
 CC regulator. An antisense molecule of the invention is useful for treating
 CC or preventing cancer, rheumatoid arthritis, psoriasis and diabetic
 CC retinopathy by inhibiting angiogenic activity or inappropriate
 CC vascularization including formation and proliferation of new blood
 CC vessels, growth and development of tissues, tissue regeneration and organ
 CC and tissue repair in a subject. The products of the invention are useful
 CC for preparing medicaments for treating wounds such as dermal ulcers,
 CC pressure sores, venous sores, diabetic ulcers and burns and to promote
 CC skin graft growth, tissue repair, proliferation of new blood vessels,
 CC tissue regeneration and organ repair by promoting angiogenic activity or
 CC vascularization. This sequence represents the human VEGF-X protein
 CC isolated from clones 4 and 7 described in the method of the invention.
 XX Sequence 345 AA;
 SQ Query Match 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 Matches 136; Conservative 0; Nsmatches 0; Indels 0; Gaps 0;
 Qy 1 LDLEDLYRPTWQILGKAFVGRKSRVVDLNLTEEVRLYSCTPRNFSVSTREELKRTDTI 60
 Db 210 ldledlyrptwqilgkafvgrkervvdnlnlteevrlysctprnfsireelkrtdti 269
 Qy 61 FWPGCLLYKRCGGNCACCLHNCNECQCYPKSVTKYHEVYLQLRPTGVYGLHKSRLDVAL 120
 Db 270 fwpgcllykrcggncacclhncneqcypksvtkyhevylqlrptgvrglhksrltdval 329
 Qy 121 EHHEECDCYCGRSTGG 136
 Db 330 ehheecdvcvrgstgg 345
 RESULT 12
 AAB10636 standard; Protein: 345 AA.
 XX AAB10636;
 XX DT 19-JAN-2001 (first entry)
 DE Human VEGF-X protein #2 isolated from clones 4 and 7.
 XX KW VEGF-X; vascular endothelial growth factor; human; vulnerability; cytostatic;
 KW antidiabetic; antiarthritic; antipsoriatic; treatment;
 AC AAB10644;

KW KW angiogenesis regulator; vascularization regulator; cancer; psoriasis;
 KW rheumatoid arthritis; diabetic retinopathy; blood vessel; organ repair;
 KW tissue regeneration; tissue repair; wound; dermal ulcer; pressure sore;
 KW venous sore; diabetic ulcer; burns; skin graft growth.
 OS Homo sapiens.
 OS OS Homo sapiens.
 OS PN WO200037641-A2.
 OS XX PD 29-JUN-2000.
 OS XX XX 29-JUN-2000.
 OS XX 99WO-US30503.
 OS PR 21-DEC-1999; 99GB-0028377.
 OS PR 22-DEC-1998; 98GB-0028377.
 OS PR 18-MAR-1999; 99US-0124567.
 OS PR 08-NOV-1999; 99US-0164131.
 OS PR 18-MAR-1999; 99US-0124567.
 OS PR 08-NOV-1999; 99US-0164131.
 OS PR 08-NOV-1999; 99US-0164131.
 OS PA (JAN) JANSSEN PHARM NV.
 OS PT Gordon RD, Sprengel JJ, Yon JR, Dijkmans JH, Gosiewska A;
 OS PI Dhanaraj SN, Xu J.;
 OS PI XX DR 2000-442669/38.
 OS DR N-PSDB; AAA71955.
 OS XX PT New vascular endothelial growth factor protein, useful for treating or
 OS PT preventing diseases associated with inappropriate angiogenesis activity
 OS PT such as cancer, rheumatoid arthritis, psoriasis and wounds -
 OS PS XX Claim 1; Fig 10; 127pp; English.
 OS XX This invention describes a novel vascular endothelial growth factor-X
 OS CC (VEGF-X) protein (ta) and its encoding polynucleotide (ta) which has
 OS CC vulnerability, cytostatic, antirheumatic, antiarthritic, antipsoriatic and
 OS CC antidiabetic activity and acts as an angiogenesis and vascularization
 OS CC regulator. An antisense molecule of the invention is useful for treating
 OS CC or preventing cancer, rheumatoid arthritis, psoriasis and diabetic
 OS CC retinopathy by inhibiting angiogenic activity or inappropriate
 OS CC vascularization including formation and proliferation of new blood
 OS CC vessels, growth and development of tissues, tissue regeneration and organ
 OS CC and tissue repair in a subject. The products of the invention are useful
 OS CC for preparing medicaments for treating wounds such as dermal ulcers,
 OS CC pressure sores, venous sores, diabetic ulcers and burns and to promote
 OS CC skin graft growth, tissue repair, proliferation of new blood vessels,
 OS CC tissue regeneration and organ repair by promoting angiogenic activity or
 OS CC vascularization. This sequence represents the human VEGF-X protein
 OS CC isolated from clones 4 and 7 described in the method of the invention.
 OS SQ Sequence 345 AA;
 OS Query Match 100.0%; Score 754; DB 21; Length 345;
 OS Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 OS Matches 136; Conservative 0; Nsmatches 0; Indels 0; Gaps 0;
 OS Qy 1 LDLEDLYRPTWQILGKAFVGRKSRVVDLNLTEEVRLYSCTPRNFSVSTREELKRTDTI 60
 OS Db 210 ldledlyrptwqilgkafvgrkervvdnlnlteevrlysctprnfsireelkrtdti 269
 OS Qy 61 FWPGCLLYKRCGGNCACCLHNCNECQCYPKSVTKYHEVYLQLRPTGVYGLHKSRLDVAL 120
 OS Db 270 fwpgcllykrcggncacclhncneqcypksvtkyhevylqlrptgvrglhksrltdval 329
 OS Qy 121 EHHEECDCYCGRSTGG 136
 OS Db 330 ehheecdvcvrgstgg 345
 OS RESULT 12
 OS AAB10644 standard; Protein: 345 AA.
 OS XX AAB10644;
 OS XX DT 19-JAN-2001 (first entry)
 OS DE Human VEGF-X protein #2 isolated from clones 4 and 7.
 OS XX KW VEGF-X; vascular endothelial growth factor; human; vulnerability; cytostatic;
 OS KW antidiabetic; antiarthritic; antipsoriatic; treatment;
 OS AC AAB10644;

XX 19-JAN-2001 (first entry)

XX Human VEGF-X protein #4.

XX VEGF-X; vascular endothelial growth factor; human; vulnery; cytostatic; antirheumatic; antiarthritic; antipsoriatic; antidiabetic; treatment; angiogenesis regulator; vascularization regulator; cancer; psoriasis; rheumatoid arthritis; diabetic retinopathy; blood vessel; organ repair; tissue regeneration; tissue repair; wound; dermal ulcer; pressure sore; venous sore; diabetic ulcer; burns; skin graft growth.

XX OS Homo sapiens.

XX PN WO200037641-A2.

XX PD 29-JUN-2000.

XX PF 21-DEC-1999; 99WO-US30503.

XX PR 22-DEC-1998; 98GB-0028377.

XX PR 18-MAR-1999; 99US-0124667.

XX PR 08-NOV-1999; 99US-0164131.

XX PA (JANC) JANSSEN PHARM NV.

XX PI Gordon RD, Sprengel JJ, Yon JR, Dijkmans JJJ, Gosiewska A; Dhanaraj SN, Xu J;

XX PI WPI; 2000-442669/38.

XX DR N-PSDB; AAA71990.

XX PT New vascular endothelial growth factor protein, useful for treating or preventing diseases associated with inappropriate angiogenesis activity such as cancer, rheumatoid arthritis, psoriasis and wounds -

XX PS Disclosure; Fig 30B; 127pp; English.

XX This invention describes a novel vascular endothelial growth factor-X (VEGF-X) protein (Ia) and its encoding polynucleotide (IIa) which has vulnery, cytostatic, antirheumatic, antiarthritic, antipsoriatic and antidiabetic activity and acts as an angiogenesis and vascularization regulator. An antisense molecule of the invention is useful for treating or preventing cancer, rheumatoid arthritis, psoriasis and diabetic retinopathy by inhibiting angiogenic activity or inappropriate vascularization including formation and proliferation of new blood vessels, growth and development of tissues, tissue regeneration and organ and tissue repair in a subject. The products of the invention are useful for preparing medicaments for treating wounds such as dermal ulcers, pressure sores, venous sores, diabetic ulcers and burns and to promote skin graft growth, tissue repair, proliferation of new blood vessels, tissue regeneration and organ repair by promoting angiogenic activity or vascularization. This sequence represents a human VEGF-X protein described in the method of the invention.

XX Sequence 345 AA;

RESULT 14

ID AAB10650 standard; Protein: 345 AA.

ID AAB10650 standard; Protein: 345 AA.

XX AAB10650;

AC AAB10650;

XX 19-JAN-2001 (first entry)

XX Human 990126vegx protein.

XX VEGF-X; vascular endothelial growth factor; human; vulnery; cytostatic; antirheumatic; antiarthritic; antipsoriatic; antidiabetic; treatment; angiogenesis regulator; vascularization regulator; cancer; psoriasis; rheumatoid arthritis; diabetic retinopathy; blood vessel; organ repair; tissue regeneration; tissue repair; wound; dermal ulcer; pressure sore; venous sore; diabetic ulcer; burns; skin graft growth.

XX OS Homo sapiens.

XX WO200037641-A2.

XX PD 29-JUN-2000.

XX PF 21-DEC-1999; 99WO-US30503.

XX PR 22-DEC-1998; 98GB-0028377.

XX PR 18-MAR-1999; 99US-0124667.

XX PR 08-NOV-1999; 99US-0164131.

XX PA (JANC) JANSSEN PHARM NV.

XX PI Gordon RD, Sprengel JJ, Yon JR, Dijkmans JJJ, Gosiewska A; Dhanaraj SN, Xu J;

XX PI WPI; 2000-442669/38.

XX PT New vascular endothelial growth factor protein, useful for treating or preventing diseases associated with inappropriate angiogenesis activity such as cancer, rheumatoid arthritis, psoriasis and wounds -

XX DR Disclosure; Fig 11; 127pp; English.

XX This invention describes a novel vascular endothelial growth factor-X (VEGF-X) protein (Ia) and its encoding polynucleotide (IIa) which has vulnery, cytostatic, antirheumatic, antiarthritic, antipsoriatic and antidiabetic activity and acts as an angiogenesis and vascularization regulator. An antisense molecule of the invention is useful for treating or preventing cancer, rheumatoid arthritis, psoriasis and diabetic retinopathy by inhibiting angiogenic activity or inappropriate vascularization including formation and proliferation of new blood vessels, growth and development of tissues, tissue regeneration and organ and tissue repair in a subject. The products of the invention are useful for preparing medicaments for treating wounds such as dermal ulcers, pressure sores, venous sores, diabetic ulcers and burns and to promote skin graft growth, tissue repair, proliferation of new blood vessels, tissue regeneration and organ repair by promoting angiogenic activity or vascularization. This sequence represents the human 990126vegx protein used to illustrate the method of the invention.

XX Sequence 345 AA;

Query Match 100.0%; Score 754; DB 21; Length 345;

Best Local Similarity 100.0%; Pred. No. 4.7e-71; Mismatches 0; Indels 0; Gaps 0;

Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SQ 1 LDLEDLYRPTWQILGKAFYGRKSRSVYDNLTEFVRVLYSCTPRNFSVSIREELKRTDTI 60

Db 210 ldledlyrptwqilgkafygrksrsvvdnltefvrlyactprnvsireelkrtdti 269

Qy 61 FWPGCLLIVKRCGGNCACCLHNCNEQCQCPVKTYHEVQLRPTKGVRALKHSLTDVAL 120

Db 270 fwpgcllivkrcggncacclhncneqcqcpktykhevqlrptkgvralkhsltdval 329

Qy 121 EHHEPCDCVCRG-STGG 136

Db 330 ehhecdcvcrgstgg 345

Qy 61 FWPGCLLIVKRCGGNCACCLHNCNEQCQCPVKYHEVQLRPTKGVRALKHSLTDVAL 120

Db	270	fwpgcllvkrqgnaccnlhncneccqcvpsktkhyhevlqrptgvrghksltcval	329	Qy	1	LDLEDLYKPTWQLLGKAVFGRKSRYVDLNLTEEVRLYSCPTPRNFVSYIREBLKRTDTI	60
Qy	121	EHHERCDCYCRG STGG	136	Db	210	ldledlyptwqllgkafvfkrsrvdnliteevrlsctprnfvsireelkrtdi	269
Db	330	ehheecdvcvrgstgg	345	Qy	61	FWPGCLLVKRCGGNACCLHNCNECCQCVPSKTYTKYHEVLQRLRPTGVRGKSLTDVAL	120
RESULT	15			Db	270	fwpgcllvkrqgnaccnlhncqcvpsktkhyhevlqrptgvrghksltcval	329
AAB10651				Qy	121	EHHECDCYCRG STGG	136
ID	AAB10651	standard;	Protein;	Db	330	ehheecdvcvrgstgg	345
XX				RESULT	16		
AC	AAB10651;			AAB19578			
XX				ID	AAB19578	standard;	Protein;
DT	19-JAN-2001	(first entry)		XX	AAB19578;		345 AA.
XX				XX			
DE	Human VEGF-X protein #3.			AC			
XX				XX			
VEGF-X;	vascular endothelial growth factor; human; vulnerable; cytostatic;			DT	22-JAN-2001	(first entry)	
KW	antihematic; antiarthritic; antipsoriatic; antidiabetic; treatment;			DE	Human PRO200 (vascular endothelial growth factor E).		
KW	angiogenesis regulator; vascularization regulator; cancer; psoriasis;			XX	PRO200; vascular epithelial growth factor E; VEGF-E; human;		
KW	rheumatoid arthritis; diabetic retinopathy; blood vessel; organ repair;			XX	KW		
KW	tissue regeneration; tissue repair; wound; dermal ulcer; pressure sore;			XX	KW	ocular disease; retinopathy; macular degeneration; retinal detachment;	
KW	venous sore; diabetic ulcer; burns; skin graft growth.			XX	XX	KW	
OS	Homo sapiens.			XX	XX	KW	
XX				OS		KW	
PN	WO200037641-A2.			XX		retinitis pigmentosa; macular hole; myopia; traumatic chorioretinopathy;	
XX				XX		KW	
PR	29-JUN-2000.			XX		acute retinal necrosis syndrome; contusion; edema;	
PD				XX		KW	
XX				XX		retinal vision occlusion; vascular disease; retinal vasculitis;	
PF	21-DEC-1999;	99WO-US30503.		XX		KW	
PF				XX		thrombocytopenic purpura; uveitis; retinal occlusion.	
XX				OS			
XX				XX			
PR	22-DEC-1998;	98GB-0028377.		XX			
PR	18-MAR-1999;	99US-0124467.		XX			
PR	08-NOV-1999;	99US-0164131.		XX			
XX				XX			
PA	(JANCS) JANSSEN PHARM NV.			XX			
XX				XX			
PI	Gordon RD, Sprengel JJ, Yon JR, Dijkmans JH, Gostiewska A;			XX			
PI	Dhanaraj SN, Xu J;			XX			
XX				XX			
WPI:	2000-442669/38.			XX			
XX				XX			
PT	New vascular endothelial growth factor protein, useful for treating or			XX			
PT	preventing diseases associated with inappropriate angiogenesis activity			XX			
PT	such as cancer, rheumatoid arthritis, psoriasis and wounds -			XX			
XX				XX			
CC	Claim 72; Fig 12; 127pp; English.			XX			
CC	This invention describes a novel vascular endothelial growth factor-X			XX			
CC	(VEGF-X) protein (ta) and its encoding polynucleotide (tta) which has			XX			
CC	vulnerary, cytostatic, antiarthritic, antipsoriatic and			XX			
CC	antidiabetic activity and acts as an angiogenesis and vascularization			XX			
CC	regulator. An antisense molecule of the invention is useful for treating			XX			
CC	or preventing cancer, rheumatoid arthritis, psoriasis and diabetic			XX			
CC	retinopathy by inhibiting angiogenic activity or inappropriate			XX			
CC	vascularization including formation and proliferation of new blood			XX			
CC	vessels, growth and development of tissues, tissue regeneration and organ			XX			
CC	and tissue repair in a subject. The products of the invention are useful			XX			
CC	for preparing medicaments for treating wounds such as dermal ulcers,			XX			
CC	pressure sores, venous sores, diabetic ulcers and burns and to promote			XX			
CC	skin graft growth, tissue repair, proliferation of new blood vessels,			XX			
CC	tissue regeneration and organ repair by promoting angiogenic activity or			XX			
CC	vascularization. This sequence represents the human VEGF-X protein			XX			
CC	described in the method of the invention.			XX			
XX				XX			
SQ	Sequence 345 AA;			XX			
Query Match	100.0%	Score 754;	DB 21;	Length 345;			
Best Local Similarity	100.0%	Pred. No. 4.7e-71;					
Matches	136;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;		
PI	Ferrara N, Goddard A, Gurney AL, Hebert C, Henzel WJ, Kabakoff RC;						
PI	Klein RD, Kjavin IJ, Kuo SS, La Fleur M, Wood WI;						
XX							
DR	WPI: 2000-587437/55.						
DR	N-PSDB; AAA88515.						

selected from systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central and peripheral nervous systems, hepatobiliary diseases, inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune or immune-mediated skin diseases, allergic diseases, immunological diseases of the lung, and transplantation associated diseases including graft rejection and graft-versus-host disease.

AAC58397 to AAC58578 represent PCR primers and hybridisation probes used in the isolation of human PRO sequences. AAC58379 to AAC58642 and AAB33414 to AAB34477 represent human PRO polynucleotide and protein sequences given in the exemplification of the present invention.

Sequence 345 AA;

Query Match 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 Matches 136; Conservative 0; Mismatches 0; Gaps 0;
 AC AAB24412;

Qy 1 LDLEDLYRPTWQLLGKAFVFGKRSRVDLNLTTEYRPLYSCPRNFSVSTREBLKRDTI 60
 Db 210 ldledlyrptwqllgkafvfgkrsrvdlnltteavrlsctprnfsvireelkrtdt 269

Qy 61 FWPGCLLIVKRCGGNCACCLNNECCOCPVSKTAKYTHEVILQRLPKTGVRGLHKSLSLVAL 120
 Db 270 fwgcllivkrcggncacclnneccgvpvsktvkyhevlgqrpktgvrghkslval 329

Qy 121 EHHEECDCVCRGSGTGG 136
 Db 330 ehheecdccvcrqsgtgg 345

RESULT 18

AAB24412 standard; Protein; 345 AA.
 XX AAB24412;

DT 07-NOV-2000 (first entry)

XX Human PRO713 protein sequence SEQ ID NO:137.

KW Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation; diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy; angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic; cytostatic; gene therapy; vaccine.
 XX Homo sapiens.
 XX WO200032221-A2.

PD 08-JUN-2000.

XX PF 30-NOV-1999; 99WO-US28313.
 XX PR 01-DEC-1998; 98WO-US25108.
 PR 16-DEC-1998; 98US-0112850.
 PR 12-JAN-1999; 99US-0115554.
 PR 08-MAR-1999; 99WO-US05038.
 PR 12-MAR-1999; 99US-0123957.
 PR 28-APR-1999; 99US-0131445.
 PR 14-MAY-1999; 99US-0134287.
 PR 02-JUN-1999; 99WO-US12522.
 PR 23-JUN-1999; 99US-0141037.
 PR 20-JUL-1999; 99US-0144758.
 PR 26-JUL-1999; 99US-0145598.
 PR 01-SEP-1999; 99WO-US20111.
 PR 08-SEP-1999; 99WO-US20394.
 PR 13-SEP-1999; 99WO-US20944.

PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 29-OCT-1999; 99US-0162506.
 XX (GETH) GENENTECH INC.

XX PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillian KJ, Goddard A; PI Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF, Smith V; PI Watanabe CK, Williams PM, Wood WI;
 XX WPI: 2000-412154/35.
 DR N-PSDB; AAA77321.

XX Nucleic acids encoding PRO polypeptides useful for preventing,

PT diagnosing and treating diagnosing a cardiovascular, endothelial or

PT angiogenic disorders in mammals.

XX

PS Claim 72; Fig 50; 315pp; English.

XX The present invention describes nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating diagnosing a cardiovascular, endothelial or angiogenic disorder in mammals by modulating cell proliferation, angiogenesis and cardiovascularisation, and for identifying agonists and antagonists of these processes. The nucleic acids and the proteins they encode may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PRO expression such as cardiovascular, endothelial or angiogenic disorders in mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For example, the nucleic acids (NCS) and vectors containing them and the PRO polypeptide may be used to treat disorders associated with decreased PRO expression. AAA77510 to AAA77721 and AAB24388 to AAB24435 represent nucleotide and protein sequences used in the exemplification of the present invention.

XX

PS Sequence 345 AA;

Query Match 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LDLEDLYRPTWQLLGKAFVFGKRSRVDLNLTTEYRPLYSCPRNFSVSTREBLKRDTI 60
 Db 210 ldledlyrptwqllgkafvfgkrsrvdlnltteavrlsctprnfsvireelkrtdt 269

QY 61 FWPGCLLIVKRCGGNCACCLNNECCOCPVSKTAKYTHEVILQRLPKTGVRGLHKSLSLVAL 120
 Db 270 fwgcllivkrcggncacclnneccgvpvsktvkyhevlgqrpktgvrghkslval 329

QY 121 EHHEECDCVCRGSGTGG 136
 Db 330 ehheecdccvcrqsgtgg 345

Query Match 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 LDLEDLYRPTWQLLGKAFVFGKRSRVDLNLTTEYRPLYSCPRNFSVSTREBLKRDTI 60
 Db 210 ldledlyrptwqllgkafvfgkrsrvdlnltteavrlsctprnfsvireelkrtdt 269

QY 61 FWPGCLLIVKRCGGNCACCLNNECCOCPVSKTAKYTHEVILQRLPKTGVRGLHKSLSLVAL 120
 Db 270 fwgcllivkrcggncacclnneccgvpvsktvkyhevlgqrpktgvrghkslval 329

QY 121 EHHEECDCVCRGSGTGG 136
 Db 330 ehheecdccvcrqsgtgg 345

RESULT 19

ID AAB01419 standard; Protein; 345 AA.

XX AAB01419;

AC AC;

DT 20-OCT-2000 (first entry)

XX Human TANGO 128.

KW TANGO; 128; 140; 197; 212; 224; modulating agent; asthma;

KW graft; versus host diseases; rheumatoid arthritis; psoriasis;

KW inflammatory bowel disease; septic shock; ulcerative colitis;

KW Crohn's disease; chronic myelogenous leukaemia; cancer; liver

KW disease; Hodgkin's disease; osteoarthritis; Lyme's disease;

KW cachexia; autoimmune disease; myasthenia gravis; autoimmune diabetes;

KW systemic lupus erythematosus; transgenic animal; diagnosis;

KW prognosis; prophylactic; therapeutic; human.

KW	reproductive tissue; reproductive tissue; developmental disorder; cell
KW	proliferative disorder; immune disorder; reproductive disorder;
KW	cardiovascular disorder; bacterial infection; viral; fungal; parasitic;
KW	cancer; allergy; asthma; arteriosclerosis; therapy; diagnosis;
XX	XX
OS	Homo sapiens.
WO200039284-A1.	
XX	06-JUL-2000.
XX	23-DEC-1999; 99WO-US31025.
XX	30-DEC-1998; 98US-0223546.
(MILL-) MILLENNIUM PHARM INC.	
XX	Holtzman DA;
XX	WPI; 2000-465743/40.
N-PSDB; AAA47452.	
XX	Novel nucleic acid sequences encoding TANGO-128, 140, 197, 212, 213, 224 and 239 polypeptides useful for the treatment of asthma, rheumatoid arthritis, psoriasis and autoimmune diseases
XX	Claim 8; Fig 1; 209PP; English.
CC	Nucleic acids encoding TANGO polypeptides are useful as modulating agents for regulating cellular processes like asthma, graft versus-host disease, rheumatoid arthritis, psoriasis, inflammatory bowel disease, septic shock, ulcerative colitis, Crohn's disease, chronic myelogenous leukemia, cancer, liver disease, Hodkin's disease, osteoarthritis, Lyme's disease, cachexia and autoimmune diseases e.g. myasthenia gravis, autoimmune diabetes and systemic lupus erythematosus. The nucleic acids are also useful for producing transgenic animals and the TANGO polypeptides themselves. Partial TANGO-128, 140, 197, 212, 213, 224, 239 sequences are useful in forensic biology, for diagnostic assays, prognostic assays, pharmacogenomics and for monitoring clinical trials. TANGO polypeptides are suitable for both prophylactic and therapeutic methods for treating a subject at risk of a disorder or having a disorder associated with aberrant TANGO expression. A wide range of cellular disorders can be treated.
CC	Sequence 345 AA;
CC	Query Match 100.0%; Score 754; DB 21; Length 345; Best Local Similarity 100.0%; Pred. No. 4.7e-71; Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db	1 LDDEDLYRPTWQIIGKAFVGRKSRYVVDLNLTTEEVRLYSCPTPRNFSVIRDEBLKRDTI 60 210 1dledlyrptwqIigkafvgrksryvvdlnltteevrllyscptprnfsvirdeblkrtdi 269
QY	61 FWPGLCLYVRCGGNCACCLHNCACQCPVSKVTKYHEVLOLRPKTGVRGLKSLTDVAL 120 270 fwpgcllyvrcggncacclhncacqcpvskvtkylevqirptgvrqglnksldval 329
Ddb	121 EHHBECDCVCRGSGTGG 136 330 ehheecdcvcrgrsgtgg 345
XX	RERESULT 20 AAB03003 standard; Protein; 345 AA.
XX	25-SEP-2000 (first entry)
XX	Human growth factor related molecule GFRP-4.
XX	Human GFRP-4; growth factor related molecule; BMP-1; inflammation; bone morphogenic protein 1; BMP-1; inflammatory; immune response;
XX	XX

XX This sequence represents human growth factor related molecule GFRP-4.
 CC CDNA encoding GFRP-4 was initially identified in a diseased breast
 CC tissue cDNA library, and the present sequence is encoded by a consensus
 CC cDNA derived from several overlapping and/or extended cDNA clones.
 CC GFRP-4 has chemical and structural homology with human bone
 CC morphogenetic protein 1 (BMP-1) (27% identity at the BMP-1 C-terminus).
 CC GFRP-4 was found by Northern analysis to be expressed in reproductive
 CC and cardiovascular tissue, and in cDNA libraries associated with cancer,
 CC inflammation and the immune response. GFRP proteins (AAB03000-B03033),
 CC nucleotides encoding them (AAA3455-N52459), GFRP agonists and
 CC antagonists may be used to treat a wide variety of diseases associated
 CC with increased or decreased expression or activity of GFRP proteins.
 CC Conditions which may be treated include developmental disorders, cell
 CC proliferative disorders (e.g., cancers), immune disorders (e.g.,
 CC allergies, asthma), reproductive disorders (e.g., menstrual cycle
 CC disorders) cardiovascular disorders (e.g., arteriosclerosis) and
 CC bacterial, viral, fungal or parasitic infections. Additionally, GFRP
 CC proteins and nucleotides can be used in the diagnosis of such disorders.
 XX Sequence 345 AA;

Query Match Similarity 100.0%; Score 754; DB 21; Length 345;
 Best Local Similarity 100.0%; Pred. No. 4.7e-71; Indels 0; Gaps 0;
 Matches 136; Conservative 0; Mismatches 0;
 QY 1 LDLEDLYRPTMQLGAFYRFRKSRYVQLNLTEEVRLYSTCPRNFSSVSIKEELKRTDTI 60
 Db 210 ldledlyrptmqlgafyfrksryvqlnlteevrlystcprnfssvsiireelkrtdti 269
 QY 61 FWPGCLLIVKRGGNACCLHNNECOCVPSKVTKKYHEVILQRLPKTGVRGLIHKSLIDVAL 120
 Db 270 fwpgcllivkrggnacclhnnecocvpskvtkkyhevilqlrpktgvrqlihksldval 329
 QY 121 EHHEECDCVCRGSGTGG 136
 Db 330 eheecdccvrgstgg 345

RESULT 21

AAY96658

ID AAY96658 standard; Protein; 345 AA.

XX

AC AAY96658;

XX DT 26-SEP-2000 (first entry)

XX DE Human growth factor homologue, ZVEGF3.

XX

XX KW Vascular endothelial growth factor; homologue; zvegf3; CUB domain;

KW Cysteine knot; platelet-derived growth factor; PDGF; neuropilin;

KW chromosome 4q28.3; cytosolic; anti-inflammatory;

KW anti-diabetic; ophthalmological; anti-rheumatic; anti-arthritis;

KW vulvar.

XX OS Homo sapiens.

XX FH Key

Peptide 1..14

/label= secretary-peptide

FT Domain

FT /label= CUB-domain

/note= "forms beta-barrel structure with nine
FT distinct beta-strand like regions"

FT Region 48..51

/label= Beta-strand-like_region-1

FT Region 55..59

/label= Beta-strand-like_region-2

FT Region 72..78

/label= Beta-strand-like_region-3

FT Region 85..90

/label= Beta-strand-like_region-4

FT

FT Region 92..94
 FT /label= Beta-strand-like_region-5
 FT Region 107..112
 FT /label= Beta-strand-like_region-6
 FT Region 119..123
 FT /label= Beta-strand-like_region-7
 FT Region 139..146
 FT /label= Beta-strand-like_region-8
 FT Region 156..163
 FT /label= Beta-strand-like_region-9
 FT Peptide 164..234
 FT /label= Propeptide-like_sequence
 FT Cleavage-site 231..232
 FT /note= "Potential cleavage site"
 FT Cleavage-site 231..234
 FT /note= "Furin or furin-like protease target site"
 FT Domain 234..345
 FT /label= Growth_Factor_Domain
 FT /note= "Characterized with cystine knot structure"
 FT Disulfide-bond 250..296
 FT /note= "forms part of cystine knot"
 FT Region 251..259
 FT /label= Beta-strand-like_region-1
 FT Region 275..279
 FT /label= Beta-strand-like_region-2
 FT Disulfide-bond 280..335
 FT /note= "forms part of cystine knot"
 FT Disulfide-bond 284..337
 FT /note= "forms part of cystine knot"
 FT Region 297..301
 FT /label= Beta-strand-like_region-5
 FT Region 329..334
 FT /label= Beta-strand-like_region-6
 XX WO200034474-A2.
 XX PD 15-JUN-2000.
 XX PF 07-DEC-1999;
 XX PR 07-DEC-1998;
 XX PR 06-JUL-1999;
 XX PR 21-OCT-1999;
 XX PR 12-NOV-1999;
 XX PA (ZYMO) ZYMOGENETICS INC.
 XX DR 2000-4-23420/36.
 XX PI Gao Z, Hart CE, Piddington CS, Sheppard PO, Shoemaker KE;
 XX PI Glibertson DG, West JW;
 XX DR N-PSDB; AAY51498, AAY51499.
 XX PT Novel zvegf3 polypeptides and nucleotides encoding them useful for
 PT stimulating growth of smooth muscle cells and fibroblasts comprising an
 PT epitope bearing portion of a specific amino acid sequence
 XX PS Claim 1; Page 149; 173pp; English.

XX This is a human vascular endothelial growth factor homologue, designated
 CC ZVEGF3. Polypeptides comprising an epitope-bearing portion human or
 CC murine ZVEGF3 are claimed. The growth factors comprise a growth factor
 CC domain and a CUB domain (generic sequence motifs are shown in AAY96859
 CC and AAY96860). The growth factor domain is characterized by an
 CC arrangement of cysteine residues and beta-strands that is characteristic
 CC of the "cystine knot" structure of the platelet-derived growth factor
 CC (PDGF) family. The CUB domain shows homology to CUB domains in
 CC neuropilins, human bone morphogenetic protein-1, porcine seminal plasma
 CC protein, bovine acidic seminal fluid protein and Xenopus laevis
 CC tolloid-like protein. Structural analysis and homology predict that
 CC ZVEGF3 polypeptides comprising with a second polypeptide to form multimeric
 CC proteins. The human zvegf3 gene has been mapped to chromosome 4q28.3.
 CC ZVEGF3 is useful for stimulating the growth of fibroblasts or smooth

CC muscles cells, for activating cell surface PDGF-alpha receptor and for inhibiting PDGF-alpha receptor mediated cellular processes. 2VEGF3 is useful for regulating (post-development) organ growth, regeneration and maintenance, as well as tissue maintenance and repair processes. 2VEGF3

CC antagonists are useful for treating cancer, rheumatoid arthritis, diabetic retinopathy, ischemic limb disease, peripheral vascular disease, myocardial ischaemia, vascular intimal hyperplasia, atherosclerosis, wound healing, chronic liver disease and haemangioma formation. 2VEGF3 can also be used to modulate neurite growth and development of the nervous system, and for treating neurodegenerative diseases.

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

QY 121 EHHEECDCVCRGSGGG 136
Db 330 ehheecdvcvrgstgg 345

RESULT 22

AAI84557 standard; Protein; 345 AA.

XX AAI84557;

XX 25-JUL-2000 (first entry)

XX Amino acid sequence of platelet-derived growth factor C (PDGF-C).
XX Platelet-derived growth factor C; PDGF-C; cell proliferation; growth factor; heparin; connective tissue; wound healing; VEGF-F; fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth; choriocarcinoma; Wilms tumor; mekakaryoblastic leukaemia; lung carcinoma; erythroleukemia; tissue remodelling.
XX Homo sapiens.
OS Homo sapiens.
PN WO200018212-A2.

XX 06-APR-2000.

XX 30-SEP-1999; 99WO-US22668.

XX 30-SEP-1998; 98US-0108109.

PR 12-NOV-1998; 98US-0108109.

PR 03-DEC-1998; 98US-011079.

PR 18-DEC-1998; 98US-0113002.

PR 21-MAY-1999; 99US-0134426.

PR 15-JUL-1999; 99US-0144022.

XX (LUDWIG) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

XX (UHTE-) UNIV HELSINKI LICENSING LTD.

PI Eriksson U, Aase K, Lee X, Ponten A, Uutela M, Alitalo K;
Oestman A, Heldin C, Betsholtz C;
XX WPI; 2000-29954/25.
DR N-PSDB; AAA12523.

XX Novel DNA encoding PDGF-C useful to stimulate or enhance proliferation,

PT differentiation, growth and motility of cells expressing the PDGF-C receptor -
PT receptor -
XX Claim 27: Fig 2; 135pp; English.

CC The present sequence represents human platelet-derived growth factor C (PDGF-C) (formerly designated VEGF-F). PDGF-C polypeptides have the ability to stimulate and enhance proliferation or differentiation, and/or growth or motility of cells expressing a PDGF-C receptor.

CC PDGF-C polypeptides can be used in pharmaceuticals for promoting cell proliferation, preferably in combination with one other growth factor and heparin. Pharmaceuticals comprising PDGF-C polypeptides can also be used for stimulating connective tissue or wound healing. The PDGF-C polypeptide can be enzymatically processed to generate the active truncated form of PDGF-C and used to regulate the receptor-binding specificity of PDGF-C. PDGF-C can also be used to promote fibroblast mitogenesis in a mammal and to induce PDGF alpha receptor activation. PDGF-C antagonists can be used to inhibit tumour growth of a tumour expressing PDGF-C in a mammal. Specific types of human tumours, e.g. choriocarcinoma, Wilms tumour, megakaryoblastic leukaemia, lung carcinoma and erythroleukaemia, can be identified by testing for expression of PDGF-C. PDGF-C antagonists can also be used to inhibit tissue remodelling during invasion of tumour cells into a normal population of cells. Antagonists can also be used to treat fibrotic conditions, especially found in the lung, kidney or liver.

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FWPGCLLVKRCGGNCACCLHHNCBECQVPSKVKTVKKYHEVQLQRLPKTGVRGLHKSLSLTDVAL 120
Db 270 fwpgcllvkrcggncacclhhncbecqvpskvtkkyhevqlqrlpktgvrqlhkslsldval 329

XX Sequence 345 AA;

Query Match 100.00%; Score 754; DB 21; Length 345;
Best Local Similarity 100.00%; Pred. No. 4.7e-71;
Matches 136; Conservative 0; Mismatches 0; Gaps 0;

QY 1 LDLEDLYRPTWQIIGKARYFGRSRSRVDLNLPEVRLYSCPTPRNFSVSYSTREELKRTDTI 60
Db 210 1dledlyrptwqIigkaryfgrsrsrvdlnlpevrlyscprnfsvsireelkrtdi 269

QY 61 FW

FT Peptide 214 . . . 220
 FT /note= "immunogenic epitope"
 FT Peptide 249 . . . 255
 FT /note= "immunogenic epitope"
 FT Peptide 261 . . . 267
 FT /note= "immunogenic epitope"
 XX PN WO200004183-A1.
 XX PD 27-JAN-2000.
 XX PF 14-JUL-1999; 99WO-US15783.
 XX PR 15-JUL-1998; 98US-0092922.
 XX PA (HUNA-) HUMAN GENOME SCI INC.
 XX PI Ruben SM, Young PE;
 XX DRP; 2000-182442/16.
 XX N-PSDB; AAZ48599.
 XX Novel cDNA encoding human bone morphogenic proteins, vectors, host cells and methods of recombinant production, useful for diagnosis and treatment of, e.g. bone disorders -
 XX PS Claim 11: Page 183-184; 187pp; English.
 XX The invention provides novel human bone morphogenic proteins (BMP) and nucleic acids encoding the BMPs. The BMP polypeptides can be expressed by standard recombinant methodology. Determining the presence or absence of a mutation in the polynucleotides or determining the presence or amount of expression of the polypeptides is useful for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject. The polynucleotides can also be used to prevent, treat or ameliorate a medical condition. The proteins are useful for diagnosis of disorders (e.g. osteoarthritis, cartilage defects and tissue repair), and in particular for stimulation of angiogenesis. The polynucleotides are useful as reagents for differential identification of tissues or cell types present in biological samples. The polynucleotides can be used in gene therapy to promote the growth of endothelial cells. The present sequence represents a BMP of the invention (clone HETAB62).
 XX SQ Sequence 345 AA;
 XX Query Match 100.0%; Score 754; DB 21; Length 345;
 XX Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 XX Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 LDLEDLYRTWQLLGKAFVGRSRVVDNLTEVRLYSCTPRNFSVSYSTREELKRTDTI 60
 Db 210 ldledlyrtwqllgkafvgrsrvvdnltevrlysctprnfsvsvireelkrtdti 269
 Qy 61 FWPCCLLYTKRGCGNCACCLHNCACQCVPSKVKYHEVQLRPTGVRGLHKSRUTDVAL 120
 Db 270 fwgcllytkrgcgncacclhncacqcvpskvtkkyhevqlrptgvrghksitdval 329
 Qy 121 EHHECDCVCRGSTGG 136
 Db 330 ehheecdvcvrgstgg 345
 XX RESULT 24
 AA#50980 ID AAB50980 standard: Protein; 345 AA.
 XX AC AAB50980;
 XX DT 21-MAR-2001 (first entry)
 XX DE Human PRO200 Protein.
 XX SQ Query Match 100.0%; Score 754; DB 22; Length 345;
 XX ID Best Local Similarity 100.0%; Pred. No. 4.7e-71;
 XX Matches 136; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 LDLEDLYRTWQLLGKAFVGRKSRYVVDNLTEVRLYSCTPRNFSVSYSTREELKRTDTI 60
 Db 210 ldledlyrtwqllgkafvgrsrvvdnltevrlysctprnfsvsvireelkrtdti 269

PD 29-JUN-2000.
 XX 99W0-US30503.
 PF 21-DEC-1999; 99W0-US30503.
 PR 22-DEC-1998; 98GB-0028377.
 PR 18-MAR-1999; 990S-0124967.
 PR 08-NOV-1999; 99US-0164131.
 XX
 PA (JANCS) JANSSEN PHARM NV.
 XX
 PI Gordon RD, Sprengel JJ, Yon JR, Dijkmans JJJ, Gosiewska A;
 PI Dhanaraj SN, Xu J;
 XX
 DR 2000-442669/38.
 DR N-PSDB; AAA71984.
 XX
 PT New vascular endothelial growth factor protein, useful for treating or
 PT preventing diseases associated with inappropriate angiogenesis activity
 PT such as cancer, rheumatoid arthritis, psoriasis and wounds -
 PS Disclosure; Fig 20; 127pp; English.
 XX
 CC This invention describes a novel vascular endothelial growth factor-X
 CC (VEGF-X) protein (Ia) and its encoding polynucleotide (Iia) which has
 CC vulnary, cytostatic, antirheumatic, antiarthritic, antipsoriatic and
 CC antidiabetic activity and acts as an angiogenesis and vascularization
 CC regulator. An antisense molecule of the invention is useful for treating
 CC or preventing cancer, rheumatoid arthritis, psoriasis and diabetic
 CC retinopathy by inhibiting angiogenic activity or inappropriate
 CC vascularization including formation and proliferation of new blood
 CC vessels, growth and development of tissues tissue regeneration and organ
 CC and tissue repair in a subject. The products of the invention are useful
 CC for preparing medicaments for treating wounds such as dermal ulcers,
 CC pressure sores, venous sores, diabetic ulcers and burns and to promote
 CC skin graft growth, tissue repair, proliferation of new blood vessels,
 CC tissue regeneration and organ repair by promoting angiogenic activity or
 CC vascularization. This sequence represents a human VEGF-X protein which
 CC can be expressed in Buculovirus/insect cell systems and which is
 CC described in the method of the invention.
 XX
 SQ Sequence 354 AA;
 Query Match 98.7%; Score 744; DB 21; Length 354;
 Best Local Similarity 99.3%; Pred. No. 5.4e-70;
 Matches 135; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LDLEDLYRPTWQLLGRAFVGRKSRYVVDLNLTTEEVRLYSCPTPRNFSVSIRELKRTDTI 60
 Db 219 Idledlyrptwqllgkafvgrksrvdlnltteevrlsctprnfsirelkrtdti 278
 QY 61 FWPGCILVYKRCGGNCACCLHNCNECOCVPSKTYHFLQLRPTGVRGHLKSLTDVAL 120
 Db 279 fwpgcilmvkrccgncacclhncneccqcvpskvtkkyhevqlrpktgvrgihksitdval 338
 QY 121 EHHEECDCVGRGTTGG 136
 Db 339 ehheesdcvorgstgg 354
 RESULT 29
 AAB10641
 ID AAB10641 standard; Protein: 354 AA.
 AC AAB10641;
 XX
 DT 19-JAN-2001 (first entry)
 DE Human VEGF-X protein for expression in E. coli systems.
 XX
 VEGF-X; vascular endothelial growth factor; human; vulnary; cytostatic;
 KW antirheumatic; antiarthritic; antipsoriatic; antidiabetic; treatment;
 KW angiogenesis regulator; vascularization regulator; cancer; psoriasis;

KW rheumatoid arthritis; diabetic retinopathy; blood vessel; organ repair;
 KW tissue regeneration; tissue repair; wound; dermal ulcer; pressure sore;
 KW venous sore; diabetic ulcer; burns; skin graft growth.
 XX
 Homo sapiens.
 OS
 XX
 PN WO200037641-A2.
 XX
 PD 29-JUN-2000.
 XX
 PI 21-DEC-1999; 99W0-US30503.
 XX
 PR 22-DEC-1998; 98GB-0028377.
 PR 18-MAR-1999; 990S-0124967.
 PR 08-NOV-1999; 99US-0164131.
 XX
 PA (JANCS) JANSSEN PHARM NV.
 XX
 PI Gordon RD, Sprengel JJ, Yon JR, Dijkmans JJJ, Gosiewska A;
 PI Dhanaraj SN, Xu J;
 XX
 DR WPI; 2000-442669/38.
 DR N-PSDB; AAA71985.
 XX
 PT New vascular endothelial growth factor protein, useful for treating or
 PT preventing diseases associated with inappropriate angiogenesis activity
 PT such as cancer, rheumatoid arthritis, psoriasis and wounds -
 XX
 PS Disclosure; Fig 21; 127pp; English.
 XX
 CC This invention describes a novel vascular endothelial growth factor-X
 CC (VEGF-X) protein (Ia) and its encoding polynucleotide (Iia) which has
 CC vulnary, cytostatic, antirheumatic, antiarthritic, antipsoriatic and
 CC antidiabetic activity and acts as an angiogenesis and vascularization
 CC regulator. An antisense molecule of the invention is useful for treating
 CC or preventing cancer, rheumatoid arthritis, psoriasis and diabetic
 CC retinopathy by inhibiting angiogenic activity or inappropriate
 CC vascularization including formation and proliferation of new blood
 CC vessels, growth and development of tissues tissue regeneration and organ
 CC and tissue repair in a subject. The products of the invention are useful
 CC for preparing medicaments for treating wounds such as dermal ulcers,
 CC pressure sores, venous sores, diabetic ulcers and burns and to promote
 CC skin graft growth, tissue repair, proliferation of new blood vessels,
 CC tissue regeneration and organ repair by promoting angiogenic activity or
 CC vascularization. This sequence represents a human VEGF-X protein which
 CC can be expressed in E. coli systems and which is described in the method
 CC of the invention.
 XX
 SQ Sequence 354 AA;
 Query Match 98.7%; Score 744; DB 21; Length 354;
 Best Local Similarity 99.3%; Pred. No. 5.4e-70;
 Matches 135; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 LDLEDLYRPTWQLLGRAFVGRKSRYVVDLNLTTEEVRLYSCPTPRNFSVSIRELKRTDTI 60
 Db 219 Idledlyrptwqllgkafvgrksrvdlnltteevrlsctprnfsirelkrtdti 278
 QY 61 FWPGCILVYKRCGGNCACCLHNCNECOCVPSKTYHFLQLRPTGVRGHLKSLTDVAL 120
 Db 279 fwpgcilmvkrccgncacclhncneccqcvpskvtkkyhevqlrpktgvrgihksitdval 338
 QY 121 EHHEECDCVGRGTTGG 136
 Db 339 ehheesdcvorgstgg 354
 RESULT 29
 AAB48658
 ID AAB48658 standard; Protein: 345 AA.
 XX
 AC AAB48658;
 XX
 DT 19-JAN-2001 (first entry)
 DE Human VEGF-X protein for expression in E. coli systems.
 XX
 VEGF-X; vascular endothelial growth factor; human; vulnary; cytostatic;
 KW antirheumatic; antiarthritic; antipsoriatic; antidiabetic; treatment;
 KW angiogenesis regulator; vascularization regulator; cancer; psoriasis;

XXX	09-MAR-2001	(first entry)	QY	1 LDLEDLYRPTWQLLGKRAFVFGKRSRVDFLNLTEEVRLYSCPTPRNSYSIREELKRTDTI
XX	Mouse zvegf3,	SEQ ID NO:35.	Db	210 vddlslyptwgkqkaygksskvvnllkeevklyscptprnsysireelkrtdt 269
XX	Mouse; zvegf3; zvegf4 fusion; growth factor homologue; VEGF/PDGF family; murine; CUB domain; PDGF-like activity; mitogenic; osteogenic; neovascularisation; tissue repair; proliferation; differentiation; liver damage; neuroregenerative; Alzheimer's disease; multiple sclerosis; periodontal disease; bone fracture; wound healing; vascular; ischaemia; immunomodulation; hepatic.		QY	61 FNPGCCLWKRCCGNCACCLHNNCOCQVPSKTTKKVHYVLQRPKTGVRLHKSLLTDYAL 120
XX	Mus musculus.		Db	270 fwpgcclivkrccgncacclhnnecqvpktvkkhyavilqirpktrgkqglhkslltdal 329
XX	W0200066736-A1.		QY	121 EHHEECDCVCRGTTGG 136
XX	09 -NOV -2000.		Db	330 ehheecdvcrgnagg 345
XX	03 -MAY -2000; 2000090-US60047.	RESULT 31		
XX	03 -MAY -1999; 99US-0304216.	ID AAY96861 standard; Protein; 345 AA.		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	AC		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	AAV96861;		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	DT	26 -SEP -2000 (first entry)	
XX	03 -MAY -1999; 99US-0304216.	DE	Murine vascular endothelial growth factor homologue, ZVEGF3.	
XX	10 -NOV -1999; 99US-0164463.	DE	Vascular endothelial growth factor; homologue; zvegf; CUB domain; Cysteine knot; platelet-derived growth factor; PDGF; neuropilin; chromosome 4q28.3; cytostatic; anti-psoriatic; anti-inflammatory; anti-diabetic; ophthalmological; anti-rheumatic; anti-arthritis; pulmonary.	
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX		
XX	03 -MAY -2000; 2000090-US60047.	XX		
XX	03 -MAY -1999; 99US-0304216.	XX		
XX	10 -NOV -1999; 99US-0164463.	XX		
XX	04 -FEB -2000; 2000095-0180169.	XX		
XX	(ZYMO) ZYMOGENETICS INC.	XX		
XX	Gilbert T, Hart CE, Sheppard PO, Gilbertson DG;	XX		
XX	WPI: 2000-687541/67.	XX		
XX	N PSDLB; AAC81583.	XX</td		

CC maintenance, as well as tissue maintenance and repair processes. zVEGF3
 CC antagonists are useful for treating cancer, rheumatoid arthritis,
 CC diabetic retinopathy, ischemic limb disease, peripheral vascular
 CC disease, myocardial ischemia, vascular intimal hyperplasia,
 CC atherosclerosis, wound healing, chronic liver disease and haemangioma
 CC formation. zVEGF3 can also be used to modulate neurite growth and
 CC development of the nervous system, and for treating neurodegenerative
 CC diseases.

XX Sequence 345 AA;

Query Match 92.4%; Score 697; DB 21; Length 345;
 Best Local Similarity 89.0%; Pred. No. 4.4e-65;
 Matches 121; Conservative 11; Mismatches 4; Indels 0; Gaps 0;
 CC

QY 1 LDLEDLYRPTWQOLGKAFVFGRKSRVVDLNLTBEVRLYSCTPRNFVSVTREELKRTDTI 60
 Db 210 vddslslykptwqolgkafvfgrksskvvnlnlkeeekvlyscptprnfsvsireelkrtdti 269

QY 61 FWPGCLLVRKGNCACCLHCNECQVPSKVKTKYHEVILQLRPTGVRLHKSLTDVAL 120
 Db 270 fwpgcllvrkgncacclhcnecqvpskvtkkyhevqlrptgvrlhksltval 329

QY 121 EHBECDCVCRGSFTGG 136
 Db 330 ehheecdvcvrgnagg 345

RESULT 32
 ID AAY84559 standard; Protein; 345 AA.
 XX AAY84559;

XX DT 25-JUL-2000 (first entry)

XX DE A murine Platelet-derived growth factor C (PDGF-C).
 XX

Platelet-derived growth factor C; PDGF-C; cell proliferation;
 KW growth factor; heparin; connective tissue; wound healing; VEGF-F;
 KW fibroblast mitogenesis; PDGF alpha receptor activation; tumour growth;
 KW choriocarcinoma; Wilms tumour; megakaryoblastic leukaemia;
 KW lung carcinoma; erythroleukemia; tissue remodelling.

XX OS sp.

XX PN WO2000118212-A2.

XX PD 06-APR-2000.

XX PF 30-SEP-1999; 99W0-US22668.
 XX PR 30-SEP-1998; 98US-0102461.
 PR 12-NOV-1998; 98US-0108109.
 PR 03-DEC-1998; 98US-0110749.
 PR 18-DEC-1998; 98US-0113002.
 PR 21-MAY-1999; 99US-0135426.
 PR 15-JUL-1999; 99US-0144022.

XX PA (LUDW-) LUDWIG INST. CANCER RES.
 PA (UTHE-) UNIV HELSINKI LICENSING LTD.

XX PI Eriksson U, Aase K, Lee X, Ponten A, Uutela M, Alitalo K;
 PI Oestman A, Heldin C, Betsholtz C;

XX DR WPI; 2000-292954/25.
 DR N-PSDB; AAA12525.

XX Novel DNA encoding PDGF-C useful to stimulate or enhance proliferation,
 PT differentiation, growth and motility of cells expressing the PDGF-C
 PT receptor -
 XX

PS Claim 27; Fig 6; 135pp; English.

XX The present sequence represents murine platelet-derived growth factor C
 CC (PDGF-C) (formally designated VEGF-F). PDGF-C polypeptides have the
 CC ability to stimulate and enhance proliferation or differentiation,
 CC and/or growth or motility of cells expressing a PDGF-C receptor.
 CC PDGF-C polypeptides can be used in pharmaceuticals for promoting cell
 CC proliferation, preferably in combination with one other growth factor
 CC and heparin. Pharmaceuticals comprising PDGF-C polypeptides can also
 CC be used for stimulating connective tissue or wound healing. The
 CC PDGF-C polypeptide can be enzymatically processed to generate the active
 CC truncated form of PDGF-C and used to regulate the receptor-binding
 CC specificity of PDGF-C. PDGF-C can also be used to promote fibroblast
 CC mitogenesis in a mammal, and to induce alpha receptor activation.
 CC PDGF-C antagonists can be used to inhibit tumour growth of a tumour
 CC expressing PDGF-C in a mammal. Specific types of human tumours, e.g.
 CC choriocarcinoma, Wilms tumour, megakaryoblastic leukaemia, lung carcinoma
 CC and erythroleukaemia, can be identified by testing for expression of
 CC PDGF-C. PDGF-C antagonists can also be used to inhibit tissue
 CC remodelling during invasion of tumour cells into normal population of
 CC cells. Antagonists can also be used to treat fibrotic conditions,
 CC especially found in the lung, kidney or liver.

XX SQ Sequence 345 AA;

Query Match 92.4%; Score 697; Pred. No. 4.4e-65;
 Best Local Similarity 89.0%; Mismatches 4; Indels 0; Gaps 0;
 CC Matches 121; Conservative 11; Mismatches 4;

QY 1 LDLEDLYRPTWQOLGKAFVFGRKSRVVDLNLTBEVRLYSCTPRNFVSVTREELKRTDTI 60
 Db 210 vddslslykptwqolgkafvfgrksskvvnlnlkeeekvlyscptprnfsvsireelkrtdti 269

QY 61 FWPGCLLVRKGNCACCLHCNECQVPSKVKTKYHEVILQLRPTGVRLHKSLTDVAL 120
 Db 270 fwpgcllvrkgncacclhcnecqvpskvtkkyhevqlrptgvrlhksltval 329

QY 121 EHBECDCVCRGSFTGG 136
 Db 330 ehheecdvcvrgnagg 345

XX Search completed: August 29, 2001, 09:46:55
 Job time: 31 sec

